2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors

Bioorganic & Medicinal Chemistry Letters
1998.0

Abstract

A new family of PDE4 inhibitors based on a benzimidazole framework is described. Several of these compounds are orally bioavailable and show efficacy in in vivo models of inflammatory disease.

Knowledge Graph

Similar Paper

2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors
Bioorganic & Medicinal Chemistry Letters 1998.0
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma
Bioorganic & Medicinal Chemistry Letters 2000.0
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors
Bioorganic & Medicinal Chemistry Letters 2002.0
Phthalazine PDE4 inhibitors. Part 2: The synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives
Bioorganic & Medicinal Chemistry Letters 2001.0
7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 Inhibitors: A Potential Treatment for Asthma
Bioorganic & Medicinal Chemistry Letters 2002.0
Synthesis and structure–activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1- hi ]indoles: novel PDE4 inhibitors
Bioorganic & Medicinal Chemistry Letters 2000.0
Novel imidazophenoxazine-4-sulfonamides: Their synthesis and evaluation as potential inhibitors of PDE4
Bioorganic & Medicinal Chemistry 2013.0
In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors
Bioorganic & Medicinal Chemistry 2016.0
Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors
Bioorganic & Medicinal Chemistry 2013.0
Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site
Bioorganic & Medicinal Chemistry Letters 1995.0